Clinical, EEG and Radiological Initial and Evolutive Characterisation of LGI1-antibody Patients

Hospices Civils de Lyon1 site in 1 country192 target enrollmentOctober 30, 2019

ConditionsAnti-LGI1 Encephalitis

Overview

Phase: N/A
Intervention: Not specified
Conditions: Anti-LGI1 Encephalitis
Sponsor: Hospices Civils de Lyon
Enrollment: 192
Locations: 1
Primary Endpoint: Evolution of epileptic seizures
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Autoimmune encephalitis involve autoantibodies targeting central nervous system, and particularly the synapse or its structure like for LGI1 protein. Anti-LGI1 encephalitis is revealed by an inflammation of the limbic system, with mainly temporal lobe, faciobrachial dystonic or generalized seizures, and cognitive disorders.

This disease is rare and its clinical, EEG and radiological characterisation is not sufficiently established. The investigators will evaluate these three aspects for the anti-LGI1 cohort of patients of the National Reference Center of autoimmune encephalitis.

Registry

clinicaltrials.gov

Start Date

October 30, 2019

End Date

December 30, 2020

Last Updated

6 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Hospices Civils de Lyon

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Age \> 18 years
•Diagnosis of anti-LGI1 encephalitis based on sera or CSF samples in the National Reference Center of autoimmune encephalitis from 2011/06 to 2019 july 1st.
•Clinical follow-up in France